Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Reisin

Showing results (41-50 of 60) with videos related to

Pageof 6
Sort By:
The Journal of Membrane Biology|January 1, 1973
Barriers to sodium movement across frog skinJ H Moreno, I L Reisin, E Rodríguez Boulan, et al.
American Heart Journal|August 2, 2001
The dual endothelin receptor antagonist tezosentan acutely improves hemodynamic parameters in patients with advanced heart failureC Schalcher, G Cotter, L Reisin, et al.
American Journal of Therapeutics|July 29, 1999
Safety of prostaglandin E1 for the treatment of peripheral arterial occlusive disease in patients with congestive heart failure. The Alprostadil InvestigatorsL Reisin, A Marmor, B Rabinowitz, et al.
Journal of Human Hypertension|December 1, 1999
Prior antihypertensive treatment and admission blood pressure correlated with clinical outcome and early morning presentation in hypertensive ischaemic stroke patientsC Yosefy, L Linov, J R Viskoper, et al.
The American Journal of Cardiology|March 15, 1997
Comparison of short- and long-term prognosis in patients with anterior wall versus inferior or lateral wall non-Q-wave acute myocardial infarction. Secondary Prevention Reinfarction Israeli Nifedipine Trial (SPRINT) Study GroupM Haim, H Hod, L Reisin, et al.
American Heart Journal|March 7, 1998
Adding the new calcium antagonist mibefradil to patients receiving long-term beta-blocker therapy results in improved antianginal and antiischemic efficacyA Schneeweiss, I Kobrin, V Charlon, et al.
Cardiology|September 1, 1997
Prognostic significance of infarction location in patients with recurrent myocardial infarction. SPRINT Study Group. Secondary Prevention Reinfarction Israel Nifedipine TrialR Kornowski, U Goldbourt, H Reicher-Reiss, et al.
The Journal of Biological Chemistry|August 12, 1994
The cystic fibrosis transmembrane conductance regulator is a dual ATP and chloride channelI L Reisin, A G Prat, E H Abraham, et al.
Journal of Clinical Epidemiology|June 1, 1995
Plasma fibrinogen levels and their correlates in 6457 coronary heart disease patients. The Bezafibrate Infarction Prevention (BIP) StudyE Barasch, M Benderly, E Graff, et al.
American Journal of Therapeutics|July 29, 1999
Prostaglandin E1 : electrophysiological safety in patients with congestive heart failure and peripheral arterial occlusive disease. The Alprostadil InvestigatorsJ C Somberg, V Yelamanchi, J Molnar, et al.
Pageof 6

Showing results (41-50 of 60) with videos related to

Sort By:
Pageof 6
The Journal of Membrane Biology|January 1, 1973
Barriers to sodium movement across frog skinJ H Moreno, I L Reisin, E Rodríguez Boulan, et al.
American Heart Journal|August 2, 2001
The dual endothelin receptor antagonist tezosentan acutely improves hemodynamic parameters in patients with advanced heart failureC Schalcher, G Cotter, L Reisin, et al.
American Journal of Therapeutics|July 29, 1999
Safety of prostaglandin E1 for the treatment of peripheral arterial occlusive disease in patients with congestive heart failure. The Alprostadil InvestigatorsL Reisin, A Marmor, B Rabinowitz, et al.
Journal of Human Hypertension|December 1, 1999
Prior antihypertensive treatment and admission blood pressure correlated with clinical outcome and early morning presentation in hypertensive ischaemic stroke patientsC Yosefy, L Linov, J R Viskoper, et al.
The American Journal of Cardiology|March 15, 1997
Comparison of short- and long-term prognosis in patients with anterior wall versus inferior or lateral wall non-Q-wave acute myocardial infarction. Secondary Prevention Reinfarction Israeli Nifedipine Trial (SPRINT) Study GroupM Haim, H Hod, L Reisin, et al.
American Heart Journal|March 7, 1998
Adding the new calcium antagonist mibefradil to patients receiving long-term beta-blocker therapy results in improved antianginal and antiischemic efficacyA Schneeweiss, I Kobrin, V Charlon, et al.
Cardiology|September 1, 1997
Prognostic significance of infarction location in patients with recurrent myocardial infarction. SPRINT Study Group. Secondary Prevention Reinfarction Israel Nifedipine TrialR Kornowski, U Goldbourt, H Reicher-Reiss, et al.
The Journal of Biological Chemistry|August 12, 1994
The cystic fibrosis transmembrane conductance regulator is a dual ATP and chloride channelI L Reisin, A G Prat, E H Abraham, et al.
Journal of Clinical Epidemiology|June 1, 1995
Plasma fibrinogen levels and their correlates in 6457 coronary heart disease patients. The Bezafibrate Infarction Prevention (BIP) StudyE Barasch, M Benderly, E Graff, et al.
American Journal of Therapeutics|July 29, 1999
Prostaglandin E1 : electrophysiological safety in patients with congestive heart failure and peripheral arterial occlusive disease. The Alprostadil InvestigatorsJ C Somberg, V Yelamanchi, J Molnar, et al.
Pageof 6